BetaGlue Therapeutics
PrivateLast Round
VC Round
Dec 16, 2024
Total Funding Raised
$15.57M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
BetaGlue Therapeutics operates in Healthcare & Life Sciences and is based in Milan. Its latest recorded funding round was a VC Round in December 2024.
BetaGlue Therapeutics is an oncology company developing YntraDose, a radiotherapy platform designed for the localized and targeted treatment of unresectable solid tumours.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Medical Devices
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
BetaGlue Therapeutics Comparables
Compare BetaGlue Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| KORTUC INC. | 75% | |
| GT Medical Technologies | 68% | |
| OncoSil Medical Ltd | 68% |
For institutional investors. Book with your work email.
BetaGlue Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| VC Round | Dec 16, 2024 | ||||
| Grant | Mar 4, 2024 | ||||
| VC Round | Jul 28, 2022 | ||||
| Series A | Sep 7, 2016 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
BetaGlue Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| European Innovation Council Fund | Grant, VC Round |
| Neva SGR | VC Round |
| Fondazione ENEA Tech | VC Round |
| Innogest Capital | VC Round |
| Fin Posillipo S.p.A. | VC Round |
| Kairos Partners SGR | VC Round |
| Panakès Partners | VC Round, Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 25, 2026
Monthly visitors increased 245% MoM.
- May 16, 2026
Monthly visitors grew 101% MoM, reaching 1K.
For institutional investors. Book with your work email.
BetaGlue Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about BetaGlue Therapeutics's valuation, stock price, and market status.
Is BetaGlue Therapeutics a public or private company?
BetaGlue Therapeutics is a private company.
What is the current stock price of BetaGlue Therapeutics?
BetaGlue Therapeutics is a private company, so its shares have no public market price. Caplight tracks BetaGlue Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is BetaGlue Therapeutics worth (valuation)?
Valuation information for BetaGlue Therapeutics is not publicly available.
Can I buy BetaGlue Therapeutics stock?
BetaGlue Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was BetaGlue Therapeutics's last funding round?
BetaGlue Therapeutics's most recent funding round was VC Round on December 16, 2024.
Who are the main investors in BetaGlue Therapeutics?
Key investors in BetaGlue Therapeutics include Neva SGR, Panakès Partners, LIFTT EuroInvest.
Will BetaGlue Therapeutics IPO soon?
No public IPO plans have been announced for BetaGlue Therapeutics.
How can I track BetaGlue Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in BetaGlue Therapeutics's shares on secondary markets.